Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Idorsia Ltd (IDIA.SW)
Allschwil, BL, CH
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.69% | +7.61% | +21.36% | +13.93% | +39.13% | +10.00% | +172.32% | -41.89% | -81.79% | -67.28% | -67.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+96.4% ★ Q1'26: -2.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+64.1% ★ Q1'26: -178.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-69.8% Q1'26: -49.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-28.5% Q1'26: -46.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-147.3% Q1'26: -217.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+17.7% Q1'26: +38.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-27.86× Q1'26: -14.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
158.09M
est: 159.90M (-1.1%)
|
60.62M
est: 39.54M (+53.3%)
|
23.82M
est: 34.95M (-31.8%)
|
71.76M
est: 73.17M (-1.9%)
|
35.35M
est: 37.92M (-6.8%)
|
97.10M
est: 77.00M (+26.1%)
|
152.39M
est: 127.84M (+19.2%)
|
112.51M
est: 80.64M (+39.5%)
|
221.00M
est: 212.05M (+4.2%)
|
227.22M
185.95M – 271.27M
+7.2% YoY
|
291.69M
246.23M – 352.53M
+28.4% YoY
|
404.41M
400.36M – 408.45M
+38.6% YoY
|
524.94M
437.07M – 630.98M
+29.8% YoY
|
625.23M
520.57M – 751.53M
+19.1% YoY
|
| EBITDA |
2.17M
est: -159.90M (+101.4%)
|
-349.81M
est: -1.56M (-22,354.7%)
|
-457.34M
est: -301.31M (-51.8%)
|
-420.64M
est: -971.86M (+56.7%)
|
-588.84M
est: -541.07M (-8.8%)
|
-783.09M
est: -1.39B (+43.7%)
|
-254.55M
est: -107.53M (-136.7%)
|
-319.49M
est: -3.97B (+92.0%)
|
-45.49M
est: -178.37M (+74.5%)
|
-191.13M
-228.18M – -156.41M
-7.2% YoY
|
-245.36M
-296.54M – -207.12M
-28.4% YoY
|
-340.17M
-343.58M – -336.77M
-38.6% YoY
|
-441.56M
-530.76M – -367.65M
-29.8% YoY
|
-525.93M
-632.16M – -437.89M
-19.1% YoY
|
| EBIT |
-7.88M
est: -159.90M (+95.1%)
|
-371.08M
est: -2.08M (-17,714.1%)
|
-476.63M
est: -303.23M (-57.2%)
|
-439.56M
est: -1.01B (+56.4%)
|
-606.87M
est: -561.50M (-8.1%)
|
-802.92M
est: -1.44B (+44.4%)
|
-273.59M
est: -109.55M (-149.7%)
|
-337.36M
est: -4.12B (+91.8%)
|
-62.93M
est: -181.72M (+65.4%)
|
-194.72M
-232.47M – -159.35M
-7.2% YoY
|
-249.97M
-302.10M – -211.00M
-28.4% YoY
|
-346.56M
-350.03M – -343.09M
-38.6% YoY
|
-449.85M
-540.72M – -374.55M
-29.8% YoY
|
-535.80M
-644.02M – -446.10M
-19.1% YoY
|
| Net Income |
-14.27M
est: -195.03M (+92.7%)
|
-386.39M
est: -3.77M (-10,151.0%)
|
-494.65M
est: -315.75M (-56.7%)
|
-445.12M
est: -1.03B (+56.9%)
|
-634.60M
est: -574.53M (-10.5%)
|
-827.90M
est: -1.48B (+43.9%)
|
-297.92M
est: 28.66M (-1,139.5%)
|
-263.76M
est: -133.30M (-97.9%)
|
-112.00M
est: -91.09M (-23.0%)
|
-113.57M
-208.34M – -32.44M
-24.7% YoY
|
-69.65M
-159.37M – 15.47M
+38.7% YoY
|
-10.98M
-13.55M – -8.40M
+84.2% YoY
|
10.74M
8.40M – 13.55M
+197.8% YoY
|
10.74M
8.40M – 13.55M
+0.0% YoY
|
| SGA |
21.01M
est: 575.98M (-96.4%)
|
60.64M
est: 8.18M (+641.6%)
|
58.00M
est: 125.88M (-53.9%)
|
90.00M
est: 263.55M (-65.9%)
|
233.67M
est: 136.60M (+71.1%)
|
507.33M
est: 277.37M (+82.9%)
|
380.02M
est: 454.02M (-16.3%)
|
273.12M
est: 286.41M (-4.6%)
|
221.29M
est: 753.10M (-70.6%)
|
806.98M
660.40M – 963.43M
+7.2% YoY
|
1.04B
874.48M – 1.25B
+28.4% YoY
|
1.44B
1.42B – 1.45B
+38.6% YoY
|
1.86B
1.55B – 2.24B
+29.8% YoY
|
2.22B
1.85B – 2.67B
+19.1% YoY
|
| EPS |
-0.12
est: -1.07 (+88.8%)
|
-3.06
est: -2.96 (-3.5%)
|
-3.72
est: -3.59 (-3.6%)
|
-3.12
est: -2.87 (-8.6%)
|
-3.77
est: -3.53 (-6.9%)
|
-4.67
est: -4.65 (-0.4%)
|
-1.67
est: 0.16 (-1,142.8%)
|
-1.45
est: -1.78 (+18.4%)
|
-0.52
est: -0.41 (-25.3%)
|
-0.56
-0.97 – -0.15
-35.0% YoY
|
-0.36
-0.74 – 0.07
+35.7% YoY
|
-0.05
-0.06 – -0.04
+86.1% YoY
|
0.05
0.04 – 0.06
+200.0% YoY
|
0.05
0.04 – 0.06
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.16% | 1.78M | 0.40% |
| 2 | iShares Ageing Population UCITS ETF AGED.L | 0.12% | 1.08M | 0.40% |
| 3 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.10% | 3.27M | 0.30% |
| 4 | iShares MSCI Europe Small-Cap ETF IEUS | 0.09% | 155.3K | 0.41% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.08% | 283.8K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.08% | 283.8K | 0.23% |
| 7 | State Street SPDR S&P International Small Cap ETF GWX | 0.07% | 610.2K | 0.40% |
| 8 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.06% | 4.57M | 0.10% |
| 9 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.04% | 89.8K | 0.83% |
| 10 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.04% | 5.41M | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| André C. Muller | Advisor & Director | 1M | male |
| Alberto Gimona | Executive Vice President and Head of Global Clinical Development & Medical Affairs | 821.9K | male |
| Jean-Paul Clozel | Chairman of the Board & Interim CEO | 145.6K | male |
| Arno Groenewoud | Executive Vice President & Chief Financial Officer | — | — |
| Benjamin Limal | President of EUCAN Region | — | male |
| Gaby Scherer | Senior Vice President & Head of Global Human Resources | — | — |
| Julien Gander | Executive Vice President, Chief Legal & Corporate Development Officer and Company Secretary | — | male |
| Martine Clozel | Executive Vice President, Chief Scientific Officer & Head of Research | — | — |
| Olivier Lambert | Senior Vice President & Head of Technical Operations | — | male |
| Amer Joseph | Executive VP, Chief Medical Officer & Head of Global Clinical Development | — | — |
| Andrew Jones | Senior Vice President, Head of Corporate Communications & Investor Relations | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IDIA.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
